Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.
| Revenue (TTM) | $25.27B |
| Gross Profit (TTM) | $16.35B |
| EBITDA | $6.92B |
| Operating Margin | 17.80% |
| Return on Equity | 15.20% |
| Return on Assets | 7.72% |
| Revenue/Share (TTM) | $66.06 |
| Book Value | $59.94 |
| Price-to-Book | 5.42 |
| Price-to-Sales (TTM) | 4.96 |
| EV/Revenue | 5.39 |
| EV/EBITDA | 21.16 |
| Quarterly Earnings Growth (YoY) | 14.20% |
| Quarterly Revenue Growth (YoY) | 2.60% |
| Shares Outstanding | $383.36M |
| Float | $347.57M |
| % Insiders | 5.37% |
| % Institutions | 82.34% |
Volatility is currently expanding
Stryker remains a high-quality MedTech compounder despite a rare Q1 miss driven by a temporary cyber disruption. Q1 weakness was not demand-driven; full-year guidance is unchanged and end-market demand remains healthy. Current valuation reflects temporary disruption, offering a more attractive entry into SYK, though the stock is not cheap.
Rising use of automation in healthcare is reshaping robotics ETFs as med-tech innovators gain prominence.
Investors looking for stocks in the Medical - Products sector might want to consider either ICU Medical (ICUI) or Stryker (SYK). But which of these two stocks offers value investors a better bang for their buck right now?
Stryker Corporation offers a compelling medtech investment, benefiting from robust industry growth and an innovation-led strategy. SYK trades at a 13% discount to fair value, with a forward P/E of 20.1 versus a 10-year average of 25.6. Consensus expects SYK's adjusted diluted EPS to compound at 11.2% annually through 2028, supporting high single-digit dividend growth.
Stryker is a Dividend Aristocrat with 32 years of increases, robust cash flow, and a strong M&A-driven growth strategy. SYK's Q1 2026 results were impacted by a cybersecurity incident, but management maintained full-year guidance and expects normalization. The stock trades at ~21x 2026E EPS, below its 5-year average, suggesting undervaluation despite recent share price declines.
Stryker (NYSE:SYK | SYK Price Prediction) and Intuitive Surgical (NASDAQ:ISRG) both closed the books on Q1 2026 with sharply different results.
Portage, Michigan, July 01, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK) will host a webcast at 4:30 p.m. (Eastern time) on Thursday, July 30, 2026, to discuss its second quarter 2026 financial results.
Stryker (SYK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
PORTAGE, Mich., June 24, 2026 /PRNewswire/ -- Stryker (NYSE: SYK), a global leader in medical technologies, today announced a new partnership with Major Champion and globally recognized golfer Shane Lowry at the Travelers Championship in Cromwell, Connecticut, naming him a sponsored brand ambassador for its Joint Replacement division.
Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Stryker (SYK). But which of these two companies is the best option for those looking for undervalued stocks?
